Hematology

Latest News
July 31st 2025

Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 30th 2025

Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

July 29th 2025

Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

July 29th 2025

Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

July 28th 2025

Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo
Video Interviews
View All
July 29th 2025

Addressing the Hidden Burden of Polycythemia Vera: Andrew Kuykendall, MD

July 23rd 2025

Expertise Is Essential to Bispecific Access for Patients With Acute Leukemias: Amir Fathi, MD

July 17th 2025

Imetelstat Linked to Sustained Health-Related Quality-of-Life Benefits in Lower-Risk MDS: María Díez Campelo, MD, PhD

July 4th 2025

Analysis Supports Flexible Axatilimab Use in Chronic GVHD, Calls for Combination Therapy Research: Carrie Kitko, MD

July 2nd 2025

Post Hoc Analysis Supports Axatilimab in Heavily Pretreated Patients With Chronic GVHD: Carrie Kitko, MD

June 30th 2025

Why a Patient With Multiple Myeloma Might Decline Stem Cell Transplant: Mansi Shah, MD

June 29th 2025

Drivers of Cost Savings for Revumenib for Rare Acute Leukemias: Ivo Abraham, PhD, RN

June 27th 2025

How Transplant, CAR T, and Bispecifics Fit Into Myeloma Care: Mansi Shah, MD

June 25th 2025

Self-Administered Subcutaneous Isatuximab May Ease Multiple Myeloma Treatment Burden: Xavier Leleu, MD, PhD

June 24th 2025

Beat AML Master Trial Finds Strong Response With Triplet Therapy: Ashley Yocum, PhD

Podcasts
View All
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

May 5th 2018

Podcast: This Week in Managed Care—Insurance Coverage Gains Reverse and Other Health News

March 10th 2018

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

December 14th 2017

Five Years of Reducing Overuse of Medical Services With Choosing Wisely

More News

Older regimens for CLL were frequently used in older patients and were associated with significantly shorter overall survival, the authors found. | image credit: Saiful52 - stock.adobe.com
July 28th 2025

Newer Agents Should Be Used in First Line for Older Patients With CLL

AJMC Contributor
New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.
Despite the benefits associated with adequate physical function in CLL, 70% of respondents said they had never received any physical activity advice from a doctor. | Image Credit: kieferpix - stock.adobe.com.jpg
July 27th 2025

Exercise Tied to Improved Symptoms, QOL in Patients With CLL

AJMC Contributor
While physical activity was linked with improved quality of life (QOL), the majority of patients are not given the recommendation from their doctor.
In a novel finding, the study pinpointed 2 independent risk factors for AF development in this population: elevated interleukin-1β and TET2 mutation. | Image credit: mdaros - stock.adobe.com
July 27th 2025

Study Identifies Potential Genetic Drivers, Targeted Treatments for AF in MPN

AJMC Contributor
The study found that atrial fibrillation (AF) significantly increases stroke and mortality risk in certain patients with myeloproliferative neoplasms (MPNs).
In chronic lymphocytic leukemia (CLL), TP53 has been an important subject of investigation since the early 1990s. | Image credit: MdBabul - stock.adobe.com
July 25th 2025

TP53 Mutations Remain Important Research Focus in Cancer

Jared Kaltwasser
TP53 mutations can have a significant impact on the prognosis of diseases like chronic lymphocytic leukemia, but their effect can vary based on numerous factors.
Adcetris packaging | Image: Pfizer
July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Mary Caffrey
Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).
David Nguyen, MD | Image Credit: Tufts Medicine
July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD
David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Taken together, the findings suggest that the use of venetoclax following BTKi discontinuation is a feasible strategy that may help overcome toxicity-related challenges associated with long-term BTKi use. | Image credit: jarun011 - stock.adobe.com
July 23rd 2025

Venetoclax Consolidation a Feasible Strategy After BTKi in CLL

Jared Kaltwasser
Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.
Regarding survival, outcomes were similar to those seen in clinical trials of ruxolitinib for myelofibrosis. | Image credit: fotogurmespb - stock.adobe.com
July 18th 2025

Ruxolitinib Shows Sustained Clinical, QOL Benefits in MPN Real-World Data

Rose McNulty
The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life (QOL) and fewer adverse events in the real-world setting.
refractory mantle cell lymphoma | Image: Kite
July 17th 2025

After CAR T in Mantle Cell Lymphoma, Choices and a Robust Pipeline

Mary Caffrey
Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.
DLBCL | Image: Atlas of Haematological Cytology
July 16th 2025

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

Mary Caffrey
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com
July 11th 2025

Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

Rose McNulty
There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.
The findings have potential implications for treatment selection in CLL/SLL, particularly in patients at elevated risk for infectious complications. | Image credit: Eleni - stock.adobe.com
July 7th 2025

Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL

Kimberly Rath, PharmD
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.
Artwork of community health care with a giant stethoscope and medicine bag | Image credit: TarikVision - stock.adobe.com.
July 5th 2025

Academic-Community Partnerships Bringing Cancer Care to Patients

Laura Joszt, MA
Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.
Clinical trial graphic | Image credit: photon_photo - stock.adobe.com
July 5th 2025

Comparative Analysis Suggests Zanubrutinib as Most Effective cBTKi in R/R CLL

AJMC Contributor
The indirect comparative analysis is the first of its kind to assess the relative efficacy of approved covalent Bruton tyrosine kinase inhibitors (cBTKis) in the absence of head-to-head trials.
White blood cells | Image credit: Sebastian Kaulitzki - stock.adobe.com
July 2nd 2025

Basophil, Eosinophil Counts Could Be Prognostic Indicators in ET, PV

Jared Kaltwasser
The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in myeloproliferative neoplasms.
FDA approved | Image credit: DG-Studio – stock.adobe.com
Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein
This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.
Multiple myeloma words appearing on table | Image credit: ibreakstock - stock.adobe.com
July 1st 2025

Lower Tregs Linked With Survival in Multiple Myeloma

Jared Kaltwasser
The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick
The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
CLL cells | Image Credit: © sovova - stock.adobe.com
June 30th 2025

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

Jared Kaltwasser
Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Hands holding | Image credit: Africa Studio - stock.adobe.com
June 27th 2025

Understanding Patient and Caregiver Burdens in Acute Leukemia Treatment

Laura Joszt, MA
Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of life and emotional well-being.
After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
June 26th 2025

Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

Jared Kaltwasser
Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.
Multi-hit TP53 mutations are a significant negative prognostic factor for patients with both MPN and AML, the new study found. | Image credit: MdBabul - stock.adobe.com
June 20th 2025

Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

Jared Kaltwasser
Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.
Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
June 20th 2025

Venetoclax Effective in Older Patients With CLL

Jared Kaltwasser
Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.
Surbhi Sidana, MD, MBBS, Stanford University
June 19th 2025

CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS

Maggie L. Shaw Surbhi Sidana, MD, MBBS
Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)
Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
June 18th 2025

Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

Rose McNulty
Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
June 18th 2025

DVRd vs VRd in Transplant-Ineligible Myeloma: Insights From Saad Z. Usmani, MD, MBA

Maggie L. Shaw Saad Z. Usmani, MD, MBA, FACP, FASCO
CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status may affect therapeutic decision-making.
Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
June 12th 2025

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Laura Joszt, MA
Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.
The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers. | Image credit: wladimir1804 - AdobeStock_408414612
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Rose McNulty
The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.
Mansi Shah, MD
June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD
Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.
While improvements were seen in non-relapse mortality in CLL throughout the decade, the researchers observed no differences in overall survival or progression-free survival. | Image credit: LASZLO - stock.adobe.com
June 9th 2025

New Era of CLL Treatments Brings Changes to Use of HSCT

AJMC Contributor
With a 42% reduction seen in the use of hematopoietic stem cell transplantation (HSCT) throughout the decade, researchers suggest that transplantation may be reserved for more fit patients.
12345678
...
28>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo